Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era

Heather Valerio (Lead / Corresponding author), Andrew McAuley, Hamish A. Innes, Norah E. Palmateer, David J. Goldberg, Alison Munro, Avril Taylor, Sharon J. Hutchinson

Research output: Contribution to journalArticle

4 Citations (Scopus)
88 Downloads (Pure)

Abstract

Background & aims: Although people who inject drugs (PWID) are at greatest risk of hepatitis C (HCV), treatment uptake in this population has historically been low. Highly effective direct acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to assess the awareness among PWID of these new therapies and their effectiveness.

Methods: A national survey of PWID attending injecting equipment provision sites in Scotland during 2015-2016 included questions to gauge the awareness in this population of antiviral treatment and the high cure rates associated with new therapies (defined here as >80%).

Results: Among 2,623 PWID, 92% had ever been tested for HCV. After excluding those ever treated for HCV (n=226), 79% were aware of HCV treatment. Awareness was more likely among those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 95%CI 10.57–24.33) or negative (3.11, 2.30–4.22) test result, compared to those who were never tested. The minority of all respondents (17%) were aware of high cure rates. This awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13–18.60) and those who had not been in specialist care but had been tested and self-reported either a positive (3.91, 2.20–7.53) or negative (2.55, 1.35–4.81) test result, compared to those who had never been tested.

Conclusion: We found poor awareness of the high cure rates associated with DAAs among PWID in Scotland, despite relatively high rates of HCV testing in this population. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease.
Original languageEnglish
Pages (from-to)115-122
Number of pages8
JournalInternational Journal of Drug Policy
Volume52
Early online date7 Feb 2018
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Hepatitis C
Antiviral Agents
Pharmaceutical Preparations
Scotland
Population
Therapeutics
Population Groups
Chronic Disease
Odds Ratio
Drug Therapy
Equipment and Supplies
Infection
Surveys and Questionnaires

Keywords

  • Direct-acting antiviral therapy
  • Hepatitis C
  • People who inject drugs
  • Treatment effectiveness

Cite this

Valerio, Heather ; McAuley, Andrew ; Innes, Hamish A. ; Palmateer, Norah E. ; Goldberg, David J. ; Munro, Alison ; Taylor, Avril ; Hutchinson, Sharon J. / Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. In: International Journal of Drug Policy. 2018 ; Vol. 52. pp. 115-122.
@article{bbde0af4933c49349ebee7393372228d,
title = "Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era",
abstract = "Background & aims: Although people who inject drugs (PWID) are at greatest risk of hepatitis C (HCV), treatment uptake in this population has historically been low. Highly effective direct acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to assess the awareness among PWID of these new therapies and their effectiveness.Methods: A national survey of PWID attending injecting equipment provision sites in Scotland during 2015-2016 included questions to gauge the awareness in this population of antiviral treatment and the high cure rates associated with new therapies (defined here as >80{\%}).Results: Among 2,623 PWID, 92{\%} had ever been tested for HCV. After excluding those ever treated for HCV (n=226), 79{\%} were aware of HCV treatment. Awareness was more likely among those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 95{\%}CI 10.57–24.33) or negative (3.11, 2.30–4.22) test result, compared to those who were never tested. The minority of all respondents (17{\%}) were aware of high cure rates. This awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13–18.60) and those who had not been in specialist care but had been tested and self-reported either a positive (3.91, 2.20–7.53) or negative (2.55, 1.35–4.81) test result, compared to those who had never been tested.Conclusion: We found poor awareness of the high cure rates associated with DAAs among PWID in Scotland, despite relatively high rates of HCV testing in this population. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease.",
keywords = "Direct-acting antiviral therapy, Hepatitis C, People who inject drugs, Treatment effectiveness",
author = "Heather Valerio and Andrew McAuley and Innes, {Hamish A.} and Palmateer, {Norah E.} and Goldberg, {David J.} and Alison Munro and Avril Taylor and Hutchinson, {Sharon J.}",
note = "Funding: Health Protection Scotland",
year = "2018",
month = "2",
doi = "10.1016/j.drugpo.2017.12.014",
language = "English",
volume = "52",
pages = "115--122",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",

}

Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. / Valerio, Heather (Lead / Corresponding author); McAuley, Andrew ; Innes, Hamish A.; Palmateer, Norah E.; Goldberg, David J.; Munro, Alison; Taylor, Avril; Hutchinson, Sharon J.

In: International Journal of Drug Policy, Vol. 52, 02.2018, p. 115-122.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era

AU - Valerio, Heather

AU - McAuley, Andrew

AU - Innes, Hamish A.

AU - Palmateer, Norah E.

AU - Goldberg, David J.

AU - Munro, Alison

AU - Taylor, Avril

AU - Hutchinson, Sharon J.

N1 - Funding: Health Protection Scotland

PY - 2018/2

Y1 - 2018/2

N2 - Background & aims: Although people who inject drugs (PWID) are at greatest risk of hepatitis C (HCV), treatment uptake in this population has historically been low. Highly effective direct acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to assess the awareness among PWID of these new therapies and their effectiveness.Methods: A national survey of PWID attending injecting equipment provision sites in Scotland during 2015-2016 included questions to gauge the awareness in this population of antiviral treatment and the high cure rates associated with new therapies (defined here as >80%).Results: Among 2,623 PWID, 92% had ever been tested for HCV. After excluding those ever treated for HCV (n=226), 79% were aware of HCV treatment. Awareness was more likely among those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 95%CI 10.57–24.33) or negative (3.11, 2.30–4.22) test result, compared to those who were never tested. The minority of all respondents (17%) were aware of high cure rates. This awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13–18.60) and those who had not been in specialist care but had been tested and self-reported either a positive (3.91, 2.20–7.53) or negative (2.55, 1.35–4.81) test result, compared to those who had never been tested.Conclusion: We found poor awareness of the high cure rates associated with DAAs among PWID in Scotland, despite relatively high rates of HCV testing in this population. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease.

AB - Background & aims: Although people who inject drugs (PWID) are at greatest risk of hepatitis C (HCV), treatment uptake in this population has historically been low. Highly effective direct acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to assess the awareness among PWID of these new therapies and their effectiveness.Methods: A national survey of PWID attending injecting equipment provision sites in Scotland during 2015-2016 included questions to gauge the awareness in this population of antiviral treatment and the high cure rates associated with new therapies (defined here as >80%).Results: Among 2,623 PWID, 92% had ever been tested for HCV. After excluding those ever treated for HCV (n=226), 79% were aware of HCV treatment. Awareness was more likely among those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 95%CI 10.57–24.33) or negative (3.11, 2.30–4.22) test result, compared to those who were never tested. The minority of all respondents (17%) were aware of high cure rates. This awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13–18.60) and those who had not been in specialist care but had been tested and self-reported either a positive (3.91, 2.20–7.53) or negative (2.55, 1.35–4.81) test result, compared to those who had never been tested.Conclusion: We found poor awareness of the high cure rates associated with DAAs among PWID in Scotland, despite relatively high rates of HCV testing in this population. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease.

KW - Direct-acting antiviral therapy

KW - Hepatitis C

KW - People who inject drugs

KW - Treatment effectiveness

U2 - 10.1016/j.drugpo.2017.12.014

DO - 10.1016/j.drugpo.2017.12.014

M3 - Article

C2 - 29414462

VL - 52

SP - 115

EP - 122

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -